Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney DiseaseDick de Zeeuw, Glenn M. Chertow, Mark T. Houser et al.|New England Journal of Medicine|2013Cited by 990
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trialHiddo J.L. Heerspink, Chris Vercammen, Hans‐Henrik Parving et al.|The Lancet|2019Cited by 609
Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trialsHiddo J.L. Heerspink, Tom Greene, Hocine Tighiouart et al.|The Lancet Diabetes & Endocrinology|2019Cited by 372
A New Panel-Estimated GFR, Including β2-Microglobulin and β-Trace Protein and Not Including Race, Developed in a Diverse PopulationLesley A. Inker, Hans‐Henrik Parving|American Journal of Kidney Diseases|2020Cited by 73